China stops publishing asymptomatic COVID cases, reports no deaths
14 Dec 2022
Clinical Result
Preview
Source: Reuters
BEIJING, Dec 14 (Reuters) - China's National Health Commission (NHC) will as of Wednesday stop reporting new asymptomatic COVID-19 infections, as many people without symptoms no longer participate in testing, making it hard to accurately tally the total count, it said.
The health authority reported 2,291 new symptomatic COVID-19 infections on Dec. 13.
China recorded 7,679 new cases a day earlier – 2,315 symptomatic and 5,364 asymptomatic infections, which China counts separately.
Excluding imported infections, China reported 2,249 new symptomatic local cases. There were a total of 7,451 local cases including asymptomatic infections a day earlier.
There were no new deaths, the same as the previous day, keeping fatalities at 5,235.
As of Dec. 13, mainland China had confirmed 369,918 cases with symptoms.
China's capital, Beijing, reported 476 symptomatic cases, according to the NHC. That compared with 559 symptomatic and 468 asymptomatic cases the previous day, local government data showed.
Some cities reported asymptomatic case counts before the NHC's announcement.
Financial hub Shanghai reported 16 symptomatic cases and 117 asymptomatic cases, compared with 14 symptomatic cases and 115 asymptomatic cases a day before, the local health authority reported.
Guangzhou, a city in the south of nearly 19 million people, reported 533 new locally transmitted symptomatic and 741 asymptomatic cases, compared with 291 symptomatic and 434 asymptomatic cases a day before, local authorities said.
Chongqing reported 179 new symptomatic locally transmitted COVID-19 infections and 1,165 asymptomatic cases, compared with 180 symptomatic and 1,398 asymptomatic cases the previous day, local government authorities said.
Our Standards: The Thomson Reuters Trust Principles.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.